You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 7,790,704


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,790,704
Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (King Of Prussia, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan I. (Collegeville, PA)
Assignee: GlaxoSmithKline, LLC (Philadelphia, PA)
Application Number:12/141,397
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,790,704
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,790,704: Thrombopoietin Mimetics

Introduction

United States Patent 7,790,704, titled "Thrombopoietin mimetics," is a patent that covers non-peptide thrombopoietin (TPO) mimetics, along with novel processes and intermediates used in their preparation. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background of Thrombopoietin Mimetics

Thrombopoietin (TPO) is a hormone that stimulates the production of platelets in the blood. TPO mimetics are compounds designed to mimic the biological activity of TPO, which is crucial for treating conditions associated with low platelet counts, such as thrombocytopenia.

Patent Overview

Publication Number and Authority

The patent in question is US7790704B2, issued by the United States Patent and Trademark Office (USPTO)[4].

Prior Art and Legal Status

The patent lists several prior art keywords, including "oxo," "hydrazino," "ylidene," "dihydropyrazol," and "carboxylic acid." The legal status of the patent is listed as "Expired - Fee Related," indicating that the patent has expired due to non-payment of maintenance fees[4].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the composition of the TPO mimetics, their structural features, and the processes for their preparation.

  • Claim 1: This claim typically defines the broadest scope of the invention, often describing the general structure of the non-peptide TPO mimetics.
  • Claim 2-5: These claims may narrow down the scope by specifying particular structural elements or functional groups within the mimetics.

Dependent Claims

Dependent claims build upon the independent claims, providing additional details or limitations. For example:

  • Claim 6: This might specify a particular process step or intermediate used in the preparation of the TPO mimetics.

Scope of the Invention

The scope of the invention is defined by the claims and includes:

  • Non-peptide TPO mimetics: These are compounds that mimic the biological activity of TPO but are not peptides.
  • Novel processes: The patent covers new methods for preparing these mimetics, including specific intermediates and reaction steps.
  • Intermediates: The invention also includes novel intermediates used in the synthesis of the TPO mimetics[4][5].

Patent Landscape

Related Patents and Applications

The patent landscape for TPO mimetics includes other patents and applications that cover similar or related inventions. For instance, patent application US-20090176746-A1 also describes non-peptide TPO mimetics and their preparation processes[5].

Global Dossier and Patent Family

Using the Global Dossier service provided by the USPTO, one can identify the patent family for US7790704B2, which includes related applications filed at participating IP Offices. This helps in understanding the global reach and related filings of this patent[1].

Citation Data

The Common Citation Document (CCD) application can be used to consolidate prior art citations from multiple IP offices, providing a comprehensive view of the prior art landscape relevant to this patent[1].

Economic and Research Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide insights into the scope and claims of patents like US7790704B2. This dataset includes detailed information on claims from US patents and applications, which can be used to analyze trends and measurements of patent scope[3].

Economic Impact

The expiration of US7790704B2 due to non-payment of maintenance fees could have economic implications, such as opening up the market for generic or similar products. This can be analyzed using economic research datasets and studies conducted by the USPTO's Office of the Chief Economist[3].

Practical Considerations

Searching and Analyzing Patents

To conduct a thorough analysis of a patent like US7790704B2, one can use the USPTO's Patent Public Search tool, which provides enhanced access to prior art and related patent documentation. Additionally, resources like the Patent and Trademark Resource Centers (PTRCs) and the USPTO Public Search Facility can be invaluable[1].

Legal and Policy Considerations

The study on a potential small claims patent court by the Administrative Conference of the United States (ACUS) highlights the complexities and considerations involved in patent litigation. This is particularly relevant for understanding the legal landscape and potential disputes related to patents like US7790704B2[2].

Key Takeaways

  • Patent Scope: The patent covers non-peptide TPO mimetics, novel processes, and intermediates.
  • Claims Analysis: Independent and dependent claims define the scope and specific details of the invention.
  • Patent Landscape: The patent is part of a broader landscape that includes related patents and applications.
  • Economic Implications: The expiration of the patent can have significant economic impacts.
  • Practical Considerations: Utilizing USPTO resources and understanding legal and policy considerations are crucial for thorough analysis.

FAQs

What is the main subject of United States Patent 7,790,704?

The main subject of US7790704B2 is non-peptide thrombopoietin (TPO) mimetics, along with novel processes and intermediates for their preparation.

Why is the legal status of US7790704B2 listed as "Expired - Fee Related"?

The patent has expired due to the non-payment of maintenance fees.

How can one identify related patents and applications for US7790704B2?

Using the Global Dossier service provided by the USPTO, one can identify the patent family and related applications filed at participating IP Offices.

What resources can be used to analyze the scope and claims of US7790704B2?

The USPTO's Patent Public Search tool, Patent Claims Research Dataset, and resources like PTRCs and the USPTO Public Search Facility can be used.

What are the economic implications of the expiration of US7790704B2?

The expiration could open up the market for generic or similar products, potentially affecting the economic landscape related to TPO mimetics.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents - US7790704B2: https://patents.google.com/patent/US7790704B2/en
  5. Unified Patents - US-20090176746-A1: https://portal.unifiedpatents.com/patents/patent/US-20090176746-A1

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,790,704

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,790,704

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1294378 ⤷  Subscribe C300451 Netherlands ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe CA 2010 00017 Denmark ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe 91681 Luxembourg ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe SPC020/2010 Ireland ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe 10C0034 France ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe SPC/GB10/026 United Kingdom ⤷  Subscribe
European Patent Office 1294378 ⤷  Subscribe C01294378/01 Switzerland ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.